The Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) trial showed that, among patients with prior AMI and hs-CRP ≥ 2 mg/L, treatment with a monoclonal antibody targeting interleukin-1β is associated with fewer cardiovascular events [23]. Here, CRP is linked to Venous thrombosis.